Ubiquitin-proteasome system (UPS) as a target for anticancer treatment

被引：242

作者：

Park, Jinyoung ^{[1
]}

Cho, Jinhong ^{[2
]}

Song, Eun Joo ^{[2
]}

机构：

[1] Korea Inst Sci & Technol, Mol Recognit Res Ctr, Hwarangno 14 Gil 5, Seoul 02792, South Korea

[2] Ewha Womans Univ, Grad Sch Pharmaceut Sci, Coll Pharm, 52 Ewhayeodae Gil, Seoul 03760, South Korea

来源：

ARCHIVES OF PHARMACAL RESEARCH | 2020年 / 43卷 / 11期

基金：

新加坡国家研究基金会;

关键词：

Ubiquitin– proteasome system (UPS); E3; ligase; Deubiquitinating enzymes (DUBs); Proteasome; Cancer; Small molecule inhibitors; MULTIPLE-MYELOMA CELLS; CANCER THERAPEUTIC TARGET; SMALL-MOLECULE INHIBITOR; TUMOR-SUPPRESSOR CYLD; FATTY-ACID SYNTHASE; NF-KAPPA-B; BREAST-CANCER; IN-VIVO; PROMOTES PROLIFERATION; CYCLIN-E;

D O I：

10.1007/s12272-020-01281-8

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The ubiquitin-proteasome system (UPS) plays an important role in the cellular processes for protein quality control and homeostasis. Dysregulation of the UPS has been implicated in numerous diseases, including cancer. Indeed, components of UPS are frequently mutated or abnormally expressed in various cancers. Since Bortezomib, a proteasome inhibitor, received FDA approval for the treatment of multiple myeloma and mantle cell lymphoma, increasing numbers of researchers have been seeking drugs targeting the UPS as a cancer therapeutic strategy. Here, we introduce the essential component of UPS, including ubiquitinating enzymes, deubiquitinating enzymes and 26S proteasome, and we summarize their targets and mechanisms that are crucial for tumorigenesis. In addition, we briefly discuss some UPS inhibitors, which are currently in clinical trials as cancer therapeutics.

引用

页码：1144 / 1161

页数：18

共 50 条

[31] Focusing on the ubiquitin-proteasome system
不详
NATURE CELL BIOLOGY, 2005, 7 (08) : 725 - 725
[32] The ubiquitin-proteasome system and endocytosis
Strous, GJ
Govers, R
JOURNAL OF CELL SCIENCE, 1999, 112 (10) : 1417 - 1423
[33] The nuclear ubiquitin-proteasome system
von Mikecz, Anna
JOURNAL OF CELL SCIENCE, 2006, 119 (10) : 1977 - 1984
[34] Ubiquitin-proteasome system - Ubiquitin-free routes into the proteasome
Hoyt, MA
Coffino, P
CELLULAR AND MOLECULAR LIFE SCIENCES, 2004, 61 (13) : 1596 - 1600
[35] The Ubiquitin Code in the Ubiquitin-Proteasome System and Autophagy
Kwon, Yong Tae
Ciechanover, Aaron
TRENDS IN BIOCHEMICAL SCIENCES, 2017, 42 (11) : 873 - 886
[36] β-catenin is a target for the ubiquitin-proteasome pathway.
Aberle, H
Bauer, A
Stappert, J
Kispert, A
Kemler, R
FASEB JOURNAL, 1997, 11 (09): : A1409 - A1409
[37] The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib
Milano, A.
Perri, F.
Caponigro, F.
ONCOTARGETS AND THERAPY, 2009, 2 : 171 - 178
[38] Anticancer dirhodium(II,II) carboxylates as potent inhibitors of ubiquitin-proteasome system
Siu, Fung-Ming
Lin, Iris Wing-Shan
Yan, Kun
Lok, Chun-Nam
Low, Kam-Hung
Leung, Thomas Yun-Chung
Lam, Tin-Lun
Che, Chi-Ming
CHEMICAL SCIENCE, 2012, 3 (06) : 1785 - 1793
[39] Ubiquitin-proteasome system: a potential participant and therapeutic target in antiphospholipid syndrome
Wang, He
Tan, Yuan
Liu, Qi
Yang, Shuo
Cui, Liyan
FRONTIERS IN IMMUNOLOGY, 2025, 16
[40] Fluorescent reporters for the ubiquitin-proteasome system
Salomons, FA
Verhoef, LGGC
Dantuma, NP
ESSAYS IN BIOCHEMISTRY, VOL 41: THE UBIQUITIN-PROTEASOME SYSTEM, 2005, 41 : 113 - 128

← 1 2 3 4 5 →